Activity of 2-chlorodeoxyadenosine (cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-hodgkin's lymphoma

References

• Beutler E., Piro L. D., Saven A., Kay A. C., Mc Millan B., Longmire R., Carrera C. J., Morin P., Carson D. A. 2-Chlorodeoxyadenosine (2-CdA): A potent chemotherapeutic and immunosuppressive nucleoside. Leuk. Lymph 1991; 5: 1–8
   PubMed Web of Science ®Google Scholar
• Robak T. Cladribine (2-chlorodeoxyadenosine) in the treatment of haematologic malignancies. Appl. Biol. Communications 1996; 6(suppl 1)75–90
   Google Scholar
• Beutler E. Drug profiles: Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952–-956
   PubMed Web of Science ®Google Scholar
• Carrera C. J., Saven A., Piro L. D. Purine metabolism of lymphocytes. Targets for chemotherapy drug involvment. Hematol. Oncol. Clin. N. Amer 1994; 8: 357–-381
   PubMed Web of Science ®Google Scholar
• Saven A., Piro L. D. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Leuk. Lymph 1993; 11(suppl 2)109–114
   PubMed Web of Science ®Google Scholar
• Robak T., Blasińka-Morawiec M., Krykowski E., Hansz J., Komarnicki M., Kazimierczak M., Konopka L., Maj S., Hellman A., Zaucha J. M., Urasiáki J., Zdziarska B., Kotlarek-Haus S., Usnarska-Zubkiewicz L., Kuratowska Z., Dwilewicz-Trojaczek J., Holowiecki J., Krawczyk-Kuli M., Grieb P. 2-Chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk. Lymph 1996; 22: 107–11
   PubMed Web of Science ®Google Scholar
• Kay A. C., Saven A., Carrera C. J., Carson D. A., Thurston D., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Kuzel T. M., Hurria A., Samuelson E., Tallman M. S., Roeniak C. H., Jr, Rademaker A. W., Rosen S. T. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996; 87: 906–911
   PubMed Web of Science ®Google Scholar
• Hoffman M., Tallman M. S., Hakimian D., Janson D., Hogan D., Variakogis D., Kuzel T., Gordon L. J., Rai K. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J. Clin. Oncol 1994; 12: 788–792
   PubMed Web of Science ®Google Scholar
• Tefferi A., Witzig T. E., Reid J. M., Li C. Y, Ames M. M. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J. Clin. Oncol 1994; 12: 569–574
   PubMed Web of Science ®Google Scholar
• Juliusson G., Heldal W., Hippe E., Hademus M., Malm C., Wallman K., Stolt C. M., Evensen S. A., Albertioni F., Tjonfiord G., Leukei R., Liliemark J. Subcutaneus injection of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J. Clin. Oncol 1995; 13: 989–995
   PubMed Web of Science ®Google Scholar
• Liliemark J., Juliusson G. Cellular pharmacokinetics of 2-chloro-2-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin. Cancer Res 1995; 1: 385–391
   PubMed Web of Science ®Google Scholar
• Liliemark J., Juliusson G. On the pharmacokinetics of 2-chloro-2-deoxyadenosine in humans. Cancer Res 1991; 51: 5570–5572
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. High complete remission rate from 2-chloro-2-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol 1993; 11: 679–689
   PubMed Web of Science ®Google Scholar
• Robak T., Blasitnacute;ska-Morawiec M., Krykowski E., Kasznicki M., Pluzańska A., Potemski P., Hellman A., Zaucha J. M., Lewandowski K., Dmoszyńska A., Hansz J., Komarnicki M., Konopka L., Durýki T., Ceglarek B., Sikorska A., Kotlarek-Haus S., Mazur G., Urasiński J., Zdziarska B., Maj S., Kope J., Skotnicki A. B., Dwilewicz-Trojaczek J., Kuratowska Z., Grieb P. Intermittent 2-hour intravenous infusion of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk. Lymph 1996; 22: 509–-514
   PubMed Web of Science ®Google Scholar
• Juliusson G., Elmhorn-Rosenborg A., Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Eng. J. Med 1992; 327: 1056–1061
   PubMed Web of Science ®Google Scholar
• Stansfeld A. G., Diebold J., Kapanci Y., Kelenyi G., Lennert K., Mioduszewska O., Noel H., Rilke F., Sundstrom C., van Unnik J. A. M., Wright D. H. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292–293
   PubMed Web of Science ®Google Scholar
• Kazimierczuk Z., Cottam H. B., Ravanliar G. R., Robins R. K. Synthesis of 2-deoxytubercidin, 2-deoxyadenosin and related 2-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure. J. Am. Chem. Soc 1984; 106: 6379–6382
   Web of Science ®Google Scholar
• Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., Mc Fadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Warzocha K., Krykowski E., Góra-Tybor J., Fronczak A., Robak T. Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma. Leuk. Lymph 1996; 21: 343–346
   PubMed Web of Science ®Google Scholar
• Hochster H. S., Kim K., Green M. D., Mann R. B., Neiman N. S., Oken M. M., Cassileth P. A., Scott P., Ritch P., O'Connell M. J. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J. Clin. Oncol 1992; 10: 28–32
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P., Brice P., Brousse N., Caspard H., Bastion Y., Haioun C., Bosly A., Tilly H., Bordessoule D., Sebbon C., Harousseou J. L., Morel P., Dupas B., Plassart F., Vasile N., Fort N., Leporrier N. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'adulte. J. Clin Oncol 1996; 14: 514–519
   PubMed Web of Science ®Google Scholar
• Saven A., Emanuele S., Kosty M., Koziol J., Ellison D., Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated indolent non-Hodgkin's lymphoma. Blood 1995; 86: 1710–1716
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Hagemeister F. B., Romaguera J. E., Sarris A. H., Pate O., Younes A., Swan F., Keating M., Cabanillas F. Fludarabine, mitoxantrone, dexamethasone: an effective new regimen for indolent lymphoma. J. Clin. Oncol 1996; 14: 1262–1268
   PubMed Web of Science ®Google Scholar
• Fleischman R. A., Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am. J. Hematol 1995; 48: 293–299
   PubMed Web of Science ®Google Scholar
• Cheson D. D., Vena D. A., Foss F. M., Sorensen J. M. Neurotoxicity of purine analogs: a review. J. Clin Oncol 1994; 12: 2216–2228
   PubMed Web of Science ®Google Scholar